Virtu Financial’s Viridian Therapeutics VRDN Stock Holding History

Virtu Financial’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,217	Closed	-$748K	–	2300
2026 Q1	$748K	Buy	38,217 +21,160	+124%	+$628K	0.03%	421
2025 Q4	$531K	Buy	+17,057	New	+$468K	0.02%	575
2024 Q1	–	Sell	-19,456	Closed	-$424K	–	2150
2023 Q4	$424K	Buy	+19,456	New	+$307K	0.03%	462
2020 Q4	–	Sell	-7,480	Closed	-$87K	–	1832
2020 Q3	$87K	Buy	+7,480	New	+$111K	0.01%	734
2019 Q4	$25K	Buy	+3,432	New	+$35.2K	﹤0.01%	1297
2018 Q1	–	Sell	-3,460	Closed	-$541K	–	2673
2017 Q4	$541K	Buy	3,460 +2,728	+373%	+$348K	0.03%	790
2017 Q3	$100K	Buy	+732	New	+$123K	0.01%	2078

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Virtu Financial's VRDN Position: Q2 2026 in Review

Virtu Financial sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 38,217 shares — an estimated $748K sold.

Virtu Financial first reported a position in VRDN in Q3 2017 and held it in 7 quarters. The position peaked at $748K in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Virtu Financial reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 38,217 Viridian Therapeutics shares in Q2 2026, an estimated $748K.
Virtu Financial first reported a position in Viridian Therapeutics in Q3 2017 and held it in 7 quarters.
Virtu Financial's Viridian Therapeutics position peaked at $748K in Q1 2026.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.